On Tuesday 6th March and Wednesday 7th March was the 1oth Stockholm Corporate Finance Life Science Seminar, which was held at Operaterrassen over looking the Royal Castle.
There were around 500 people who were private investor’s and also people from the Life Science Sector, along with the 16 presenting companies.
My over riding thoughts are that the sector has really progressed in Sweden over the past couple of years, we have compeleted a lot of pre clinical work with great results and now have some even better results in the clinic.
There are even companies who have hit the market and are helping patients get better plus also getting revenue back into Sweden.
Bactiguard presented about the future issue of human esisstance anad the future needs to be preventative measures to ensure we get a grip on antibactiral resistenace which is a global issue.
There were a number of companies who raised the issue about the USA being so dependant on opioid use and how this is a major issue with the work force not being able to work and also the cost to society as well. 65,000 presecription are written daily for pain relief and there are 65,000 fatal over doses annually.
There also 30% of the population of the US who have fatty liver disease due to bad diet and this market is worth 200 mdkr in 2026 according to global data.
Klaria were a interesting company who have taken brown seaweed and put into on to a oral dissolvable film which has a quick release time and is easy to store for the emergency services. This I feel is a company to watch as there are so many therapy areas for this product.
I am so pleased to see how the Swedish Life Science is evolving and even more to moderate The Future of Swedish and Danish Life Science event in 2 weeks at Medicon Village.